BioSpace News Archive

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid (RNA) COVID-19 vaccine platform

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 4, 2021, after the market closes

Mirimus, Inc., a leader in conducting high-volume, high-quality PCR testing, today announced the publication of a scientific paper, titled, “Pooled Surveillance Testing Program for Asymptomatic SARS-CoV-2 Infections in K-12 Schools and Universities,” available for preprint on MedRxiv as it undergoes scientific peer review for potential publication.

Ashvattha Therapeutics, a biotech company focused on targeting diseased tissues to minimize off target toxicity and expand the therapeutic index for a wide range of drugs using novel hydroxyl dendrimer therapeutics (HDT). Preclinical results on an HDT designed to target and image brain tumors and brain metastases after systemic administration will be presented at the AACR Virtual Special Conference

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) is pleased to announce the progress of its tetrahydrocannabinol (THC)-based phase 1 clinical trial, which was approved to proceed by the U.S. Food and Drug Administration (“FDA”) on July 30, 2020, as previously disclosed.

Resolve Biosciences, the pioneer in Molecular Cartography™, today announced initial results from several prominent early access collaborations with leading laboratories across Europe

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.

Myovant Sciences, a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences

Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients in Brazil completed the recruitment of 588 patients.

Topics will include several potential first-in-class Synthetic Lethality programs, including IDE397 (Phase 1), PARG, Pol Theta and Werner Helicase